Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 2/20 | 0.71 |
| ▸ | SPR | P35270 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138804 | 0.91 | HSD11B1 (0.62) | TACR3SPRCYP2C9CYP2C19MAPK14 | |
| SCHEMBL7419173 | 0.90 | CYP2C9 (0.65) | TACR3CYP2C9CYP2C19MAPK14HTR2B | |
| SCHEMBL2931988 | 0.87 | TACR3 (0.75) | TACR3SPRCYP2C9CYP2C19MAPK14 | |
| SCHEMBL21763292 | 0.84 | TACR3 (0.71) | TACR3SPRCYP2C9CYP2C19MAPK14 | |
| SCHEMBL18620100 | 0.84 | TACR3 (0.71) | TACR3CYP2C9CYP2C19MAPK14HTR2B | |
| SCHEMBL4576675 | 0.81 | L3MBTL1 (0.64) | TACR3CYP2C9CYP2C19MAPK14HTR2B | |
| SCHEMBL21081443 | 0.81 | TACR3 (0.66) | TACR3SPRCYP2C9CYP2C19MAPK14 | |
| SCHEMBL12000466 | 0.81 | TACR3 (0.66) | TACR3CYP2C9CYP2C19MAPK14HTR2B | |
| SCHEMBL14930107 | 0.81 | TACR3 (0.66) | TACR3CYP2C9CYP2C19MAPK14HTR2B | |
| SCHEMBL2636547 | 0.80 | MEN1 (0.68) | TACR3CYP2C9CYP2C19MAPK14HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | TACR3 1336/4885SPR 1666/4885CYP2C9 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.